Characteristics of drug combination therapy in oncology by analyzing clinical trial data on clinicaltrials.gov

Pacific Symposium on Biocomputing

Volumn , Issue , 2015, Pages 68-79

  Wu, Menghua ^a,b   Sirota, Marina ^a   Butte, Atul J ^a   Chen, Bin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Harker School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; DRUG PRODUCTS; MEDICAL APPLICATIONS; NATURAL LANGUAGE PROCESSING SYSTEMS; ONCOLOGY;

COMBINATION THERAPY; COMPLEX DISEASE; DRUG COMBINATIONS; END-POINT MEASUREMENT; FUNDING SOURCES; LARGE-SCALE STUDIES; NATURAL LANGUAGES; TREATMENT RESPONSE;

DRUG THERAPY;

ANTINEOPLASTIC AGENT;

BIOLOGY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; GENETICS; HUMAN; NATIONAL HEALTH ORGANIZATION; NEOPLASMS; REGISTER; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DATA INTERPRETATION, STATISTICAL; DRUG DISCOVERY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; REGISTRIES; UNITED STATES;

EID: 84971245126     PISSN: 23356928     EISSN: 23356936     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Chen B, Butte AJ. Network medicine in disease analysis and therapeutics. Clin Pharmacol Ther. 2013 Dec;94(6):627-9.
2. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nature reviews Genetics. 2011 Jan;12(1):56-68.
3. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nature chemical biology. 2008 Nov;4(11):682-90.
4. Lee MJ, Ye AS, Gardino AK, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 2012 May 11;149(4):780-94.
5. Miller ML, Molinelli EJ, Nair JS, et al. Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Science signaling. 2013 Sep 24;6(294):ra85.
6. Mathews Griner LA, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America. 2014 Feb 11;111(6):2349-54.
7. Oncology ASoC. Shaping the Future of Oncology: Envisioning Cancer Care in 2030. 2014 Available from: http://www.asco.org/about-asco/asco-vision
8. Verweij J, Disis ML, Cannistra SA. Phase I studies of drug combinations. J Clin Oncol. 2010 Oct 20;28(30):4545-6.
9. Ananthakrishnan R, Menon S. Design of oncology clinical trials: a review. Critical reviews in oncology/hematology. 2013 Oct;88(1):144-53.
10. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the postgenomic era. Nat Biotechnol. 2012 Jul;30(7):679-92.
11. Tasneem A, Aberle L, Ananth H, et al. The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PloS one. 2012;7(3):e33677.
12. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA. 2012 May 2;307(17):1838-47.
13. Goswami ND, Pfeiffer CD, Horton JR, Chiswell K, Tasneem A, Tsalik EL. The state of infectious diseases clinical trials: a systematic review of ClinicalTrials.gov. PloS one. 2013;8(10):e77086.
14. Hill KD, Chiswell K, Califf RM, Pearson G, Li JS. Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. American heart journal. 2014 Jun;167(6):921-9 e2.
15. Hirsch BR, Califf RM, Cheng SK, et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA internal medicine. 2013 Jun 10;173(11):972-9.
16. Stockmann C, Sherwin CM, Ampofo K, et al. Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov. International journal of antimicrobial agents. 2013 Aug;42(2):161-6.
17. Aronson AR, Lang FM. An overview of MetaMap: historical perspective and recent advances. Journal of the American Medical Informatics Association : JAMIA. 2010 May-Jun;17(3):229-36.
18. U.S. Department of Health and Human Services. Guidance for Industry: Codevelopment of Two or More New Investigational Drugs for Use in Combination. Clinical Medical: 2013 June
19. Lexchin J, Bero LA, Djulbegovic Benjamin, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167
20. Bodenheimer T. Uneasy alliance: Clinical investigators and the Pharmaceutical Industry.Health Policy Report: 2000 May;342(20):1539-1544.
21. Angell M. Industry-sponsored clinical research: A broken system. JAMA. 2008;300(9):1069-1071.
22. DiMasi JA, Grabowski HG. Economics of new oncology drug development. Journal of Clinical Oncology: 2007 January;25(2): 209-216
23. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nature Reviews Drug Discovery: 2007 February;6:115-120
24. Rask-Andersen M, Masuram S, Schioth HB. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annual review of pharmacology and toxicology. 2014;54:9-26.